Classification of endometrial carcinoma: more than two types

被引:519
作者
Murali, Rajmohan [1 ,2 ]
Soslow, Robert A. [1 ,3 ]
Weigelt, Britta [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Ctr Mol Oncol, New York, NY 10065 USA
[3] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA
关键词
GYNECOLOGIC-ONCOLOGY-GROUP; UTERINE SEROUS CARCINOMA; HIGH-FREQUENCY; BREAST-CANCER; CLINICOPATHOLOGICAL ANALYSIS; MICROSATELLITE INSTABILITY; ATYPICAL HYPERPLASIA; SINGLE-NUCLEOTIDE; CLINICAL-TRIALS; CELL CARCINOMA;
D O I
10.1016/S1470-2045(13)70591-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Endometrial cancer is the most common gynaecological malignancy in Europe and North America. Traditional classification of endometrial carcinoma is based either on clinical and endocrine features (eg, types I and II) or on histopathological characteristics (eg, endometrioid, serous, or clear-cell adenocarcinoma). Subtypes defined by the different classification systems correlate to some extent, but there is substantial heterogeneity in biological, pathological, and molecular features within tumour types from both classification systems. In this Review we provide an overview of traditional and newer genomic classifications of endometrial cancer. We discuss how a classification system that incorporates genomic and histopathological features to define biologically and clinically relevant subsets of the disease would be useful. Such integrated classification might facilitate development of treatments tailored to specific disease subgroups and could potentially enable delivery of precision medicine to patients with endometrial cancer.
引用
收藏
页码:E268 / E278
页数:11
相关论文
共 86 条
[1]   A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: Toward improving individualized cancer care [J].
Abu-Rustum, N. R. ;
Zhou, Q. ;
Gomez, J. D. ;
Alektiar, K. M. ;
Hensley, M. L. ;
Soslow, R. A. ;
Levine, D. A. ;
Chi, D. S. ;
Barakat, R. R. ;
Iasonos, A. .
GYNECOLOGIC ONCOLOGY, 2010, 116 (03) :399-403
[2]  
[Anonymous], 2003, WHO CLASSIFICATION T
[3]   Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees [J].
Barlin, Joyce N. ;
Zhou, Qin ;
St Clair, Caryn M. ;
Iasonos, Alexia ;
Soslow, Robert A. ;
Alektiar, Kaled M. ;
Hensley, Martee L. ;
Leitao, Mario M., Jr. ;
Barakat, Richard R. ;
Abu-Rustum, Nadeem R. .
GYNECOLOGIC ONCOLOGY, 2013, 130 (03) :452-456
[4]   Bringing precision medicine to the clinic: from genomic profiling to the power of clinical observation [J].
Baselga, Jose .
ANNALS OF ONCOLOGY, 2013, 24 (08) :1956-1957
[5]   2 PATHOGENETIC TYPES OF ENDOMETRIAL CARCINOMA [J].
BOKHMAN, JV .
GYNECOLOGIC ONCOLOGY, 1983, 15 (01) :10-17
[6]   Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer [J].
Bose, Ron ;
Kavuri, Shyam M. ;
Searleman, Adam C. ;
Shen, Wei ;
Shen, Dong ;
Koboldt, Daniel C. ;
Monsey, John ;
Goel, Nicholas ;
Aronson, Adam B. ;
Li, Shunqiang ;
Ma, Cynthia X. ;
Ding, Li ;
Mardis, Elaine R. ;
Ellis, Matthew J. .
CANCER DISCOVERY, 2013, 3 (02) :224-237
[7]   Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial [J].
Brinton, Louise A. ;
Felix, Ashley S. ;
McMeekin, D. Scott ;
Creasman, William T. ;
Sherman, Mark E. ;
Mutch, David ;
Cohn, David E. ;
Walker, Joan L. ;
Moore, Richard G. ;
Downs, Levi S. ;
Soslow, Robert A. ;
Zaino, Richard .
GYNECOLOGIC ONCOLOGY, 2013, 129 (02) :277-284
[8]   FGFR2 as a molecular target in endometrial cancer [J].
Byron, Sara A. ;
Pollock, Pamela M. .
FUTURE ONCOLOGY, 2009, 5 (01) :27-32
[9]  
Cancer Research UK, Uterine Cancer Statistics
[10]   Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium [J].
Cao, QJ ;
Belbin, T ;
Socci, N ;
Balan, R ;
Prystowsky, MB ;
Childs, G ;
Jones, JG .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2004, 23 (04) :321-329